Product Images Methylphenidate Hydrochloride

The figure shows the average levels of methylphenidate in the bloodstream of 36 adults who were given a single dose of methylphenidate hydrochloride extended-release tablets of 18mg and immediate-release methylphenidate three times a day of 5mg each, with an interval of four hours. The measurements were taken over a period of 32 hours.*

The text describes a figure (Figure 2) that shows the Mean Community School Teacher IOWA Conners Inattention/Overactivity Scores for methylphenidate hydrochloride extended-release tablets (18, 36, or 54 mg) and placebo. The figure represents data from three studies - Studies 1 and 2 involved a 3-way crossover of 1 week per treatment arm, and Study 3 involved 4 weeks of parallel-group treatments with a Last Observation Carried Forward analysis at week 4. The error bars represent the mean plus standard error of the mean. Methylphenidate Hydrochloride, a maximum of 15 Extended-Release Tablets, once daily, were used for the study.*

The text is a figure with a graph showing the mean ratings of laboratory school teacher SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham) on the combined attention subscale. The graph shows a comparison between the effect of Methylphenidate hydrochloride extended-release tablets and Placebo on attention span. The X-axis represents attentive hours post-initial dose, and the Y-axis represents the combined attention subscale. There are no non-English characters.*

This text provides a table displaying recommended starting doses and dose ranges for Methylphenidate Hydrochloride Extended-Release Tablets based on patient's age. The table lists the recommended starting dose and dose range for children aged 6-12 years, adolescents aged 13-17 years, and adults aged 18-85 years. For adolescents, the dose should not exceed 2 mg/kg/day.*

This text presents a table showing the recommended dose conversion from methylphenidate regimens to methylphenidate hydrochloride extended-release tablets based on the previous methylphenidate daily dose. It includes the recommended starting dose of methylphenidate hydrochloride extended-release tablets for different previous doses of methylphenidate.*

The table provides data on the exposure of Methylphenidate Hydrochloride Extended-Release Tablets in double-blind and open-label clinical studies for children, adolescents, and adults. The patient population ranges from 2,216 children to 1,188 adults with a dose range of 18 to 108 mg once daily.*

This is a table presenting the adverse reactions that were reported by children and adolescent subjects treated with Methylphenidate Hydrochloride Extended-Release Tablets in four placebo-controlled, double-blind clinical trials. The table includes the name of the adverse reactions, the percentage of subjects who reported them, and a comparison with the placebo group. The adverse reactions are divided into different categories, including Gastrointestinal Disorders, General Disorders and Administration Site Conditions, Infections and Infestations, Nervous System Disorders, Psychiatric Disorders, and Respiratory, Thoracic and Mediastinal Disorders. Some of the most commonly reported adverse reactions include vomiting, dizziness, and insomnia.*

Table 6 shows the adverse reactions reported by 21% of subjects given Methylphenidate Hydrochloride in a double-blind, randomized trial. The table includes various disorders and symptoms such as gastrointestinal disorders, headache, nervousness, and infections, among others. The text appears to be a chart summarizing the findings of the trial.*

This is a pharmacokinetic study evaluating the mean and standard deviation of certain parameters after administering a single dose of Methylphenidate and Methylphenidate hydrochloride extended-release tablets to healthy adults. The study included 35 participants who were given Methylphenidate hydrochloride extended-release tablets three times a day at 5 mg and 36 participants who were given 18 mg of Methylphenidate once a day. The parameters measured were Cnax (ng/mL), Trnax (h), and AUC; (ngeh/mL). The mean and standard deviation values for each parameter are provided in the table.*

This is a description of a medication called Methylphenidate Hydrochloride Extended-Release Tablets. It lists the quantity of the drug contained in each tablet and provides storage instructions. The medication is only available with a prescription and should be kept out of reach of children. It also has an NDC number.*